86282-96-4

Usage

Uses

Used in Skincare Products:
N-Tetradecanoyl-L-proline is used as an active ingredient in skincare products for its ability to boost collagen production, which helps maintain skin elasticity and firmness. This contributes to the reduction of wrinkles and fine lines, promoting a more youthful appearance.
Used in Anti-Aging Formulations:
N-Tetradecanoyl-L-proline is used as an anti-aging agent in rejuvenating skincare formulations due to its capacity to promote skin hydration and reduce the appearance of wrinkles. Its anti-inflammatory and antioxidant properties also support skin health and protect against environmental stressors.
Used in Topical Skincare Products:
N-Tetradecanoyl-L-proline is used as a topical treatment in skincare products to improve skin texture and appearance. Its lipophilic nature allows for effective penetration of the skin, ensuring the delivery of its beneficial effects to the deeper layers where they are most needed.
Used in Cosmetic Products:
N-Tetradecanoyl-L-proline is used as a key ingredient in cosmetic products to enhance the overall health and appearance of the skin. Its multifaceted benefits, including collagen production, skin hydration, and anti-aging properties, make it a popular choice for formulations aimed at improving skin quality and reducing signs of aging.

InChI:InChI=1/C19H35NO3/c1-2-3-4-5-6-7-8-9-10-11-12-15-18(21)20-16-13-14-17(20)19(22)23/h17H,2-16H2,1H3,(H,22,23)/t17-/m0/s1

Upstream product

• 112-64-1 tetradecanoyl chloride 
• 147-85-3 L-proline 
• 112-67-4 n-hexadecanoyl chloride 

Relevant academic research and scientific papers

PH 7 INJECTABLE SOLUTION COMPRISING AT LEAST ONE BASAL INSULIN OF WHICH THE PI IS FROM 5.8 TO 8.5 AND A CO-POLYAMINO ACID BEARING CARBOXYLATE CHARGES AND HYDROPHOBIC RADICALS AND A LIMITED AMOUNT OF M-CRESOL

The invention relates to physically stable compositions in the form of an injectable aqueous solution, the pH of which is from 6.0 to 8.0, comprising at least: a) a basal insulin whose isoelectric point (pI) is from 5.8 to 8.5, b) m-cresol in a concentration lower than or equal to 30 mM (0 a co-polyamino acid bearing carboxylate charges and at least one Formula X hydrophobic radical.

INJECTABLE SOLUTION AT PH 7 COMPRISING AT LEAST ONE BASAL INSULIN FOR WHICH THE PI IS FROM 5.8 TO 8.5 AND A CO-POLYAMINO ACID BEARING CARBOXYLATE CHARGES AND HYDROPHOBIC RADICALS

A composition in the form of an injectable aqueous solution, whose pH consists from 6.0 to 8.0, including at least: a basal insulin whose isoelectric point includes from 5.8 to 8.5; a co-polyamino-acid bearing carboxylate charges and hydrophobic radicals Hy, the co-polyamino-acid being constituted of glutamic or aspartic units and said hydrophobic radicals Hy according to the following formula I:

INJECTABLE SOLUTION AT PH 7 COMPRISING AT LEAST ONE BASAL INSULIN WHEREIN THE PI IS COMPRISED FORM 5.8 TO 8.5 AND A CO-POLYAMINO ACID BEARING CARBOXYLATE CHARGES AND HYDROPHOBIC RADICALS

In one embodiment, the composition according to the invention is characterized in that the co-polyamino acid bearing carboxylate charges and at least one hydrophobic radical -Hy is chosen among the co-polyamino acids according to formula XXXb hereinafter: wherein, D represents, independently, either a group —CH2— (aspartic acid) or a group —CH2—CH2— (glutamic acid),X represents a cationic entity chosen in the group comprising alkali cations,Rb and Rb′, identical or different, are either a hydrophobic radical -Hy, or a radical chosen in the group consisting of an H, a C2 to C10 linear acyl group, a C3 to C10 branched acyl group, a benzyl, a terminal “amino acid” unit and a pyroglutamate, at least one of Rb and R′b is a hydrophobic radical -Hy,Q and Hy are as defined above.n+m represents the degree of polymerization DP of the co-polyamino acid, namely the mean number of monomeric units per co-polyamino acid chain and 5≤n+m≤250.

COMPOSITIONS IN THE FORM OF AN INJECTABLE AQUEOUS SOLUTION COMPRISING AMYLIN, AN AMYLIN RECEPTOR AGONIST OR AN AMYLIN ANALOG, AND A CO-POLYAMINO ACID

An injectable aqueous solution, of which the pH is from 6.0 to 8.0, comprising at least: a) amylin, an amylin receptor agonist or an amylin analog; b) a co-polyamino acid bearing carboxylate charges and hydrophobic radicals Hy, said co-polyamino acid consisting of glutamic or aspartic units and said hydrophobic radicals Hy having the following formula I: [in-line-formulae]?GpR?r?GpA?a?GpC)p ??I[/in-line-formulae] wherein the composition does not comprise a basal insulin of which the isoelectric point pI is from 5.8 to 8.5. It also relates to a composition wherein it moreover comprises a prandial insulin.

Compositions in the form of an injectable aqueous solution comprising human glucagon and a co-polyamino acid

An injectable aqueous solution, the pH of which is from 6.0 to 8.0, having at least: a) human glucagon, and b) a co-polyamino acid bearing carboxylate charges and hydrophobic radicals Hy. In an embodiment, the compositions have, in addition, a gastrointestinal hormone.

Injectable solution at pH7 comprising at least one basal insulin the pI of which is from 5.8 to 8.5, a prandial insulin and/or a gastrointestinal hormone, and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals

A physically stable compositions in the form of an injectable aqueous solution, the pH of which is from 6.0 to 8.0: a basal insulin of which the isoelectric point (pI) is from 5.8 to 8.5, a prandial insulin or a gastrointestinal hormone, and a co-polyamino acid bearing carboxylate charges and at least one hydrophobic radical.